Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amalian SF is a line of CE-marked monophasic hyaluronic acid dermal fillers designed for aesthetic medicine. These fillers are based on ultra-pure, fully hydrated hyaluronic acid gels produced via biofermentation and are free from animal components. The Amalian SF range includes products with varying concentrations and viscosities to address different cosmetic needs—from fine lines (e.g., Amalian SF 16 fine) to moderate wrinkles (e.g., Amalian SF 20 medium), deeper folds and volume augmentation (e.g., Amalian SF 24 advanced), and strong volumizing effects (e.g., Amalian SF 28 macro). The mechanism of action is physical volumization by space-occupying gel in the dermis or subcutaneous tissue; the product does not induce pharmacological changes but provides immediate lifting and smoothing effects that last from approximately six months up to a year depending on the specific product. All products are fully degradable by endogenous hyaluronidases. Developed in Germany by S&V Technologies, these fillers meet high safety standards for biocompatibility and sterility[1][3][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amalian SF.